Navigation Links
Therapix Biosciences Ltd. Announces Full Exercise of Underwriters' Over-Allotment Option
Date:4/3/2017

TEL-AVIV, Israel, April 3, 2017 /PRNewswire/ --

Therapix Biosciences Ltd. (NASDAQ: TRPX, TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that the underwriters of its previously announced public offering of 2,000,000 American Depository Shares (ADSs), each ADS representing 40 ordinary shares of the Company, have exercised their option to purchase an additional 300,000 ADSs, at the public offering price of $6.00 per ADS to cover over allotments, bringing total gross proceeds from the offering to $13,800,000, prior to deducting underwriting discounts and offering-related expenses payable by the Company. The public offering previously closed on March 27, 2017.  This exercise of the over-allotment closed on April 3, 2017.

Therapix plans to use the net proceeds from this offering to advance the formulation and clinical development efforts for its two lead product candidates, including Phase II clinical trials, and for working capital and other general corporate purposes.

Therapix's ADSs are traded on the NASDAQ Capital Market under the symbol TRPX.

Laidlaw & Company (UK) Ltd. is acting as sole book running manager for the offering.

The final prospectus relating to this offering was filed with the Securities and Exchange Commission (SEC) on March 22, 2017. The offering was made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained by contacting Laidlaw & Company (UK) Ltd., 546 5th Avenue, New York, New York 10036, telephone 212-953-4917, email: syndicate@laidlawltd.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  

About Therapix Biosciences Ltd. 

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company has initiated two internal drug development programs based on repurposing a U.S. Food and Drug Administration, or FDA, approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of Tourette Syndrome, and BrainBright Pharma developing THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments.

Forward-Looking Statements 

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss the use of proceeds, the description of our technology and its proposed uses. These forward-looking statements involve certain risks and uncertainties, including, among others, risks that could cause the Company's results to differ materially from those expected by Company management or otherwise described in or implied by the statements in this press release. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Therapix Biosciences Ltd.'s prospectus filed with the SEC on March 22, 2017, which is available on the SEC's website, http://www.sec.gov .

Contact: Goldfinger Communications, Irit Radia, irit@goldfingercom.com, +972-54-6699311


'/>"/>
SOURCE Therapix Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
2. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
3. Therapix Biosciences Provides Portfolio Update
4. The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
5. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
6. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
7. Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with StockNewsNow.com
8. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
9. How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma
10. Hope Biosciences Acquires Worldwide Rights To Novel MERTK/AXL Inhibitor From NeoPharm
11. Hope Biosciences Licenses nuc-Gemcitabine, A Trojan Horse Anti-nucleolin-Gemcitabine Aptamer Drug Conjugate Against Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... (PRWEB) , ... August 14, 2019 , ... ... 11,580 sf and addition of 5,217 sf. With pet care at the forefront ... care, internal medicine, cardiology, endoscopy and CT. Twelve exam rooms, office space and ...
(Date:8/14/2019)... ... 13, 2019 , ... Last week during the NCPDP Joint ... the NCPDP Real-Time Prescription Benefit (RTPB) Standard. The vote to approve the BETA ... from across the industry, with representation from all industry stakeholder groups, including government ...
(Date:8/12/2019)... ... August 12, 2019 , ... Intalere, the healthcare industry leader in delivering optimal ... in the Innovator of The Year - Health IT category of the Pittsburgh Technology ... the Pittsburgh Technology Center as a healthcare IT innovator in the Pittsburgh area,” said ...
Breaking Medicine Technology:
(Date:8/17/2019)... ARLINGTON, Texas (PRWEB) , ... August 17, 2019 ... ... 12 and 18 are receiving free dental care services today under a program ... relationship with Mission Arlington and are proud to work alongside them to make ...
(Date:8/16/2019)... , ... August 16, 2019 , ... ... and standardize pharmaceutical and non-pharmaceutical cannabidiol (CBD) products across the CBD market in ... to launch its crowdfunding campaign to raise $50 million on September 9, 2019. ...
(Date:8/16/2019)... ... August 16, 2019 , ... Tim Stouffer, ICS Safety Manager, ... North East at the 2019 Safety Academy sponsored through Associated Builders and Contractors ... safety concepts and define not only a safety program but focus on the ...
(Date:8/15/2019)... , ... August 15, 2019 , ... ... to pathology residents who have been directly affected by the closure of Hahnemann ... of donations gathered during the campaign, the ASCP Foundation will be making hardship ...
(Date:8/15/2019)... ... 15, 2019 , ... Heritage Woods of Rockford Administrator Jaclyn O’Keefe has been ... This award is part of the NCAL Awards Program, which recognizes exemplary assisted living ... among this year’s recipients is that they all go out of their way to ...
Breaking Medicine News(10 mins):